Previous Article | Next Article ![]()
J. Virol., Jul 1997, 5124-5132, Vol 71, No. 7
S Miyatake, A Iyer, RL Martuza and SD Rabkin
Tissue- or cell-specific targeting of vectors is critical to the success of
gene therapy. We describe a novel approach to virus-mediated gene therapy,
where viral replication and associated cytotoxicity are limited to a
specific cell type by the regulated expression of an essential
immediate-early viral gene product. This is illustrated with a herpes
simplex virus type 1 (HSV-1) vector (G92A) whose growth is restricted to
albumin-expressing cells. G92A was constructed by inserting an albumin
enhancer/promoter-ICP4 transgene into the thymidine kinase gene of mutant
HSV-1 d120, deleted for both copies of the ICP4 gene. This vector also
contains the Escherichia coli lacZ gene under control of the thymidine
kinase promoter, a viral early promoter, to permit easy detection of
infected cells containing replicating vector. In the adult, albumin is
expressed uniquely in the liver and in hepatocellular carcinoma and is
transcriptionally regulated. The plaquing efficiency of G92A is > 10(3)
times higher on human hepatoma cells than on non-albumin-expressing human
cells. The growth kinetics of G92A in albumin-expressing cells is delayed
compared with that of wild-type HSV-1, likely due to aberrant expression of
ICP4 protein. Cells undergoing a productive infection expressed detectable
levels of ICP4 protein, as well as the reporter gene product
beta-galactosidase. Confining a productive, cytotoxic viral infection to a
specific cell type should be useful for tumor therapy and the ablation of
specific cell types for the generation of animal models of disease.
Copyright © 1997, American Society for Microbiology
Transcriptional targeting of herpes simplex virus for cell-specific replication
Department of Neurosurgery, Georgetown University Medical Center, Washington, DC 20007, USA.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|